PMI earnings analysis
What we found in PMI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The extracted 10-Q does not provide current-period revenue, margins, EPS, balance-sheet figures, cash flow, segment results, or quantitative guidance, so operating performance cannot be assessed from the available text. The key developments are 2 continuing material weaknesses in internal controls, a conditional NYSE compliance process tied to $3.8 million of stockholders’ equity and losses in 3 of the 4 most recent fiscal years, and newly amended securities litigation. Overall sentiment is bearish because listing, financing, reporting-control, and litigation risks remain material despite acceptance of the compliance plan.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Internal-control remediation continues
- Management continued its remediation plan as of June 30, 2026, including hiring additional accounting personnel and implementing multiple-level reviews over financial reporting.
- Litigation claims were amended
- The amended securities complaint filed on July 28, 2026, dropped claims under Sections 10(b) and 20(a) and instead asserted Sections 11 and 15 claims regarding alleged omissions in the IPO registration statement.
- NYSE compliance plan accepted
- On July 22, 2026, NYSE American accepted PMI’s compliance plan, providing a path to regain compliance by November 8, 2027.
- Warrant exchange completed
- PMI exchanged existing HT Warrants for warrants to purchase 200,000 common shares at an exercise price of $17.50 per share, with a five-year term.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continuing material weaknesses
- Disclosure controls were deemed ineffective as of June 30, 2026 because of 2 continuing material weaknesses: limited segregation of duties and the lack of a formal multilevel review process. Management stated that a material misstatement could fail to be prevented or detected on a timely basis.
- Conditional continued listing
- PMI reported stockholders’ equity of $3.8 million as of December 31, 2025 and net losses in 3 of its 4 most recent fiscal years, leading to the NYSE Section 1003(a)(ii) deficiency. Although the plan was accepted on July 22, 2026, compliance remains subject to quarterly reviews and the November 8, 2027 deadline.
- Unquantified securities litigation
- The amended securities class action filed July 28, 2026 alleges material omissions in the IPO registration statement concerning market-structure or stock-price-manipulation risks. The company said the case is at an early stage and that it cannot reasonably estimate a possible loss or range of loss.
- Potential financing impact from delisting
- The filing states that delisting could reduce liquidity, limit market quotations and analyst coverage, and decrease PMI’s ability to obtain additional financing. These consequences would apply if PMI cannot list its securities on another national exchange.
What they said about what is next.
No quantitative revenue or EPS guidance was provided in the extracted 10-Q text; outlook was not disclosed.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 15, 2026
- PMI reported a strong revenue growth of 85% year-over-year for Q1 2026, reaching $1.15 million, boosted by U.S. sales. However, the company incurred a net loss of $7.6 million, which reflects ongoing operational…
- 10-K · May 14, 2026
- Picard Medical, Inc. reported mixed financial performance for 2025. Revenue indicated slight growth, with Q4 2025 revenue at $1 million, a 40.7% increase in gross margin compared to Q3, while the diluted EPS turned…
- 10-K · March 30, 2026
- Picard Medical reported $1,009,000 of revenue for the year ended December 31, 2025 and a GAAP loss per share of $0.058. The company emphasizes its unique commercial position as the only TAH approved in the U.S. and…
- 10-Q · September 12, 2025
- Picard Medical (PMI) reported total revenue of $2,131,000 for the quarter (reported as $2,131 in the filing, in thousands), up from $694,000 in Q2 2024, but still produced a quarterly gross loss of $127,000 and a net…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PMI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever